Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 6/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29236909 | 0.97 | CRBN (0.54) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL26321021 | 0.90 | CRBN (0.64) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL26321010 | 0.90 | CRBN (0.64) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL26317744 | 0.89 | CRBN (0.63) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL26323878 | 0.89 | CRBN (0.63) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL26321035 | 0.89 | CRBN (0.63) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL26323874 | 0.89 | CRBN (0.63) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL25030085 | 0.88 | CRBN (0.53) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL28907406 | 0.88 | CRBN (0.55) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL18639832 | 0.87 | CRBN (0.61) | CRBNMAP1LC3BBRD4TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024807-A1 | Lenalidomide and Thalidomide Immunoassays | SALADAX BIOMEDICAL INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130211052-A1 | Lenalidomide and Thalidomide Immunoassays | SALADAX BIOMEDICAL INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440796-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8293492-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2012-03-22 | — | — | US | disclosed |
| US-20120064549-A1 | Lenalidomide and Thalidomide Immunoassays | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| US-8114621-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110223611-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | FCGRT, MALT1, SERPINA6 | CRBN 26/4885MAP1LC3B 61/4885BRD4 504/4885 |
| US-20130211052-A1 | Lenalidomide and Thalidomide Immunoassays | FCGRT, MALT1, SERPINA6 | CRBN 26/4885MAP1LC3B 61/4885BRD4 504/4885 |
| US-20110223611-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | FCGRT, MALT1, SERPINA6 | CRBN 26/4885MAP1LC3B 61/4885BRD4 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.